Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders

1. A method of administering a total daily dosage of a dopamine replacement agent to a patient in need thereof, wherein the method comprises:

a) administering a first dosage of the dopamine replacement agent, a dopamine decarboxylase inhibitor (DDI), and a catechol-O-methyltransferase (COMT) inhibitor, wherein the first dosage comprises 20-35% of the total daily dosage of the dopamine replacement agent; and

b) continuously administering a second dosage of the dopamine replacement agent, the DDI and the COMT, wherein the second dosage comprises the remainder of the total daily dosage of the dopamine replacement agent

wherein the dopamine replacement agent is selected from the group consisting of levodopa, melevedopa, etilevodopa, derivatives thereof, and combinations thereof;

wherein the DDI is selected from the group consisting of carbidopa, benserazide, a-difluoromethyldopa and combinations thereof

wherein the COMT is selected from the group consisting of entacapone, tolcapone, opicapone and combinations thereof and

wherein at least the second dosage is administered as a liquid composition, a suspension, or a gel.

2. The method of claim 1 , wherein the step of continuously administering comprises:

a) first continuously administering a first portion of the second dosage for a predetermined time, and subsequently continuously administering a second portion of the second dosage, wherein the first and second portions together add up to the second dosage and wherein, for the second portion, a lower amount of the dopamine replacement agent is administered per time unit than is administered for the first portion.

3. The method of claim 1 , wherein the dopamine replacement agent is levodopa or a pharmaceutically acceptable salt or derivative thereof.

4. The method of claim 1 , wherein the dopamine decarboxylase inhibitor is carbidopa.

5. The method of claim 4 , wherein the COMT inhibitor is entacapone.

6. The method of claim 1 , wherein the composition further comprises a substance inhibiting degradation of carbidopa to hydrazine.

7. The method of claim 6 , wherein the substance is entacapone.

8. The method of claim 1 , wherein the dopamine replacement agent, the dopamine decarboxylase inhibitor (DDI), and the catechol-O-methyltransferase (COMT) inhibitor, and optionally suitable adjuvants are contained in a single pharmaceutical composition.

9. The method of claim 1 , wherein the pharmaceutical composition comprises a first, second and a third part, wherein the first part comprises the dopamine replacement agent, the second part comprises the dopamine decarboxylase inhibitor (DDI), and the third part comprises the catechol-O-methyltransferase (COMT) inhibitor, and wherein each part may optionally contain suitable adjuvants.

10. The method of claim 1 , wherein the pharmaceutical composition comprises:

a) a first part comprising the dopamine replacement agent and the dopamine decarboxylase inhibitor (DDI) and

b) a second part comprising the COMT inhibitor; and

wherein each part optionally contains suitable adjuvants.

11. The method of claim 1 , wherein the dopamine replacement agent, the dopamine decarboxylase inhibitor (DDI), and the catechol-O-methyltransferase (COMT) inhibitor, and optionally suitable adjuvants of the first dosage are administered individually.

12. The method of claim 1 , wherein the dopamine replacement agent and the dopamine decarboxylase inhibitor (DDI) are administered at the same time and wherein the COMT inhibitor is administered essentially at the same time as the dopamine replacement agent and the dopamine decarboxylase inhibitor (DDI).

13. The method of claim 1 , wherein the total daily dosage of dopamine replacement agent is 200 to 3500 mg.

14. The method of claim 1 , wherein the total daily dosage of dopamine replacement agent is 400-3000 mg.

15. The method of claim 1 , wherein the patient suffers from Parkinson's disease.

16. The method of claim 15 , wherein the patient suffers from hyperkinetic sensitivity or has a tendency to become hyperkinetic.

17. The method of claim 1 , wherein the continuous administration is performed continuously for 24 hours.

18. The method of claim 1 , wherein the continuous administration is performed continuously for 12-18 hours.

19. The method of claim 1 , wherein the continuous administration is performed continuously for 13-17 hours or 14-16 hours.

20. The method of claim 1 , wherein the first dosage is administered in the morning.

21. The method of claim 20 , wherein the first dosage is administered between 5 am and 10 am.

22. The method of claim 1 , wherein the composition of the first dosage is an oral composition, a liquid composition, a suspension or a gel.

23. The method of claim 22 wherein the first dosage is administered orally, intravenously, subcutaneously, intra-intestinally or dermally.

24. The method of claim 1 wherein the second dosage is administered intravenously, subcutaneously, intra-intestinally or dermally.

25. A kit comprising a first container and at least one additional container wherein the first and the at least one additional container comprises a first and a second dosage respectively of a pharmaceutical composition comprising a dopamine replacement agent, a dopamine decarboxylase inhibitor (DDI), and a catechol-O-methyltransferase (COMT) inhibitor, wherein:

a) the first dosage comprises 20-35% of the total daily dosage of the dopamine replacement agent; the second dosage comprises the remainder of the total daily dosage of the dopamine replacement agent; and

b) at least the second dosage is a liquid, a suspension or a gel,

wherein the dopamine replacement agent is selected from the group consisting of levodopa, melevedopa, etilevodopa, derivatives thereof, and combinations thereof;

wherein the DDI is selected from the group consisting of carbidopa, benserazide, a-difluoromethyldopa and combinations thereof, and

wherein the COMT is selected from the group consisting of entacapone, tolcapone, opicapone and combinations thereof.

26. The kit according to claim 25 , wherein both the first and second dosages are liquids, suspensions or gels.